Residual Disease Mergers & Acquisitions

Acquire.fyi monitors the latest mergers and acquisitions. Since 2025, 1 M&A deals in the Residual Disease category have pushed the total transaction value to $1.5B.

M&A Deals (2026)

0% vs 2025 year-to-date

Total Value (2026)

$1.5B

0% vs 2025 year-to-date

Median Deal Size (2026)

$1.5B

0% vs 2025 year-to-date

Megadeals: >$500M

0% vs 2025 year-to-date

M&A Deal Volume & Value

Historical performance in the Residual Disease category.

Source: Acquire.fyi, Jan 1, 2025 - Jul 21, 2026.

Top Residual Disease Deals (Last 12 Months)

Largest mergers and acquisitions by disclosed deal value.

Acquirer	Target	Type	Value	Headline
Tempus AI, Inc.	Personalis, Inc.	Acquisition	$1.5B	Tempus Buys Personalis to Lock In MRD Testing

Latest Residual Disease Articles

Page 1 of latest articles and deal coverage.

Technology | Jul 20, 2026

Tempus Buys Personalis to Lock In MRD Testing

The $1.5 billion deal gives Tempus direct control of a fast-growing cancer monitoring asset as reimbursement and clinical adoption begin to scale.

Related M&A Categories

Artificial Intelligence Healthcare IT Biotechnology Precision Medicine Oncology